Search
for
Sort by
Research 31–60 of 1000+
- P063 Tracking down autoantibodies
- Hypertrichosis of the eyelashes caused by bimatoprost
- Rational Design and Synthesis of 4-((1<i>R</i>,2<i>R</i>)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a Novel, Nonsteroidal Androgen Receptor Antagonist Devoid of Phototoxicity for Dermatological Indications
- Transverse Leukonychia and Beau Lines Following COVID-19 Vaccination
- EU Legal and Regulatory Update
- A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States
- Healthcare innovation and patent law’s ‘pharmaceutical privilege’: is there a pharmaceutical privilege? And if so, should we remove it?
- COVID-19: The question of genetic diversity and therapeutic intervention approaches
- Patient characteristics associated with all-cause healthcare costs of alopecia areata in the United States
- Industry update: the latest developments in the field of therapeutic delivery, July 2018
- Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations
- Association of alopecia areata with COVID-19 vaccination: A vaccine adverse events reporting system analysis
- COVID-19 Infection and Vaccination Effects on Breast Implant Illness: A Case Report
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For
- The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction
- Investigation of drug partition property in artificial sebum
- Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata
- 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production
- The women’s hair growth questionnaire: Development and validation of a patient-reported measure for treatment efficacy in androgenetic alopecia
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Treatment of Alopecia Areata With Tofacitinib
- Relative uptake of minoxidil into appendages and stratum corneum and permeation through human skin in vitro
- Reactivation of Alopecia Areata After Dupilumab Therapy for Atopic Dermatitis
- Rational Design of a Topical Androgen Receptor Antagonist for the Suppression of Sebum Production with Properties Suitable for Follicular Delivery
- Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- Facial hair treatment in transgender and gender diverse adults: a survey of barriers and satisfaction
- Current Landscape and Emerging Therapies in Hair Loss Treatment for Androgenetic Alopecia
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos